Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: A comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val

Journal of Virology

Volumn 73, Issue 10, 1999, Pages 8448-8456

  Sharma, Prem L ^a   Crumpacker, Clyde S ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; COMPLEMENTARY DNA; LAMIVUDINE; LEUCINE; METHIONINE; RNA DIRECTED DNA POLYMERASE; VALINE;

ARTICLE; ENZYME KINETICS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; VIRION; VIRUS MUTATION; VIRUS RECOMBINANT; VIRUS REPLICATION;

EID: 0032875344     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.73.10.8448-8456.1999     Document Type: Article

References (46)

1. Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
2. Arion, D., N. Kaushik, S. McCormick, G. Borkow, and M. A. Parnaik. 1998. Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 37: 15908-15917.
3. Back, N. K., M. Nijhuis, W. Keulen, C. A. Boucher, B. O. Oude Essink, A. B. van Kuilenburg, A. H. van Gennip, and B. Berkhout. 1996. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J. 15:4040-4049.
4. Bebenek, K., W. A. Beard, T. A. Darden, L. Li, R. Prasad, B. A. Luxon, D. G. Gorenstein, S. A. Wilson, and T. A. Kunkel. 1998. A minor groove binding track in reverse transcriptase. Nat. Struct. Biol. 4:194-197.
5. Boyer, P. L., and S. H. Hughes. 1995. Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 39:1624-1628.
6. Boyer, P. L., C. Tantillo, A. Jacoba-Molina, R. G. Nanni, J. Ding, E. Arnold, and S. H. Hughes. 1994. Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length; the sensitivity of drug-resistant mutants does not. Proc. Natl. Acad. Sci. USA 91:4882-4886.
7. Boyer, P. L., H. Q. Gao, and S. H. Hughes. 1998. A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template primer. Antimicrob. Agents Chemother. 42:447-452.
8. Caliendo, A. M., A. Savara, D. An, K. DeVore, J. C. Kaplan, and R. T. D'Aquila. 1996. Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication. J. Virol. 70:2146-2153.
9. Carmichael, A., X. Jin, P. Sissons, and L. Borysiewicz. 1993. Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocytes (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease. J. Exp. Med. 177:249-256.
10. Chun, T. W., L. Stuyver, S. B. Mizell, L. A. Ehler, J. A. Mican, M. Baseler, A. L. Lloyd, M. A. Nowak, and A. S. Fauci. 1997. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 94:13193-13197.
11. Coffin, J. M. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483-489.
12. Croteau, G., L Doyon, D. Thibeault, G. McKercher, L. Pilote, and D. Lamarre. 1997. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J. Virol. 71:1089-1096.
13. De Antoni, A., A. Foli, J. Lisziewicz, and F. Lori. 1997. Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy. J. Infect. Dis. 176:899-903.
14. de Jong, M. D., C. A. B. Boucher, G. J. Galasso, M. S. Hirsch, E. R. Kern, J. M. A. Lange, and D. D. Richman. 1996. Consensus symposium on combined antiviral therapy. Antiviral Res. 29:5-29.
15. Englund, J. A., C. J. Baker, C. Raskino, R. E. McKinney, B. Petrie, M. G. Fowler, D. Pearson, A. Gershon, G. D. McSherry, E. J. Abrams, J. Schliozberg, and J. L. Sullivan. 1997. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) study 152 Team. N. Engl. J. Med. 336:1704-1712.
16. Eron, J. J., Y. K. Chow, A. M. Caliendo, J. Videler, K. M. Devore, T. P. Cooley, H. A. Liebman, J. C. Kaplan, M. S. Hirsch, and R. T. D'Aquila. 1993. pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo. Antimicrob. Agents Chemother. 37:1480-1487.
17. Finzi, D., M. Hermankova, T. Pierson, L. M. Carruth, C. Buck, R. E. Chaisson, T. C. Quinn, K. Chadwick, J. Margolick, R. Brookmeyer, J. Gallant, M. Markowitz, D. D. Ho, D. D. Richman, and R. F. Siliciano. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295-1300.
18. Furman, P. A., J. A. Fyfe, M. H. St. Clair, K. Weinhold, J. L. Rideout, G. A. Freeman, S. N. Lehman, D. P. Bolognesi, S. Broder, H. Mitsuya, and D. W. Barry. 1986. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl. Acad. Sci. USA 83:8333-8337.
19. Goudsmit, J., A. D. Ronde, D. D. Ho, and A. S. Perelson. 1996. Human immunodeficiency virus fitness in vivo: calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase. J. Virol. 70: 5662-5664.
20. Goudsmit, J., A. de Ronde, E. de Rooij, and R. de Boer. 1997. Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 sub-populations differing at reverse transcriptase codons 41 and 215. J. Virol. 71: 4479-4484.
21. Gougeon, M-L., H. Lecoeur, A. Dulioust, M.-G. Enouf, M. Crouvoisier, C. Goujard, T. Debord, and L. Montagnier. 1996. Programmed cell death in peripheral lymphocytes from HIV-infected persons: increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression. J. Immunol. 156:3509-3520.
22. Gu, Z., Q. Gao, X. Li, M. A. Parnaik, and M. A. Wainberg. 1992. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine. J. Virol. 66:7128-7135.
23. Gulick, R. M., J. W. Mellors, D. Havlir, J. J. Eron, C. Gonzalez, D. McMahon, D. D. Richman, F. T. Valentine, L. Jonas, A. Meibohm, E. A. Emini, and J. A. Chodakewitz. 1997. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337:734-739.
24. Hammer, S., D. A. Katzenstein, M. D. Hughes, H. Gundacker, R. T. Schooley, R. H. Haubrich, W. K. Henry, M. M. Lederman, J. P. Phair, M. Niu, M. S. Hirsch, and T. C. Merigan, for the ACTG 175 Study Team. 1996. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N. Engl. J. Med. 335:1081-1090.
25. Harrigan, P. R., S. Bloor, and B. A. Larder. 1998. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro. J. Virol. 72:3773-3778.
26. Ho, D. D., A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard, and M. Markowitz. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (London) 373:123-126.26.
27. Hoffenbach, A., P. Langlade-Demoyen, G. Dadaglio, E. Vilmer, F. Michel, C. Mayaud, B. Autran, and F. Plata. 1989. Unusually high frequencies of HIV-specific cytotoxic T lymphocytes in humans. J. Immunol. 142:452-462.
28. Holodniy, M., L. Mole, D. Margolis, J. Moss, H. Dong, E. Boyer, M. Urdea, J. Kolberg, and S. Eastman. 1995. Determination of human immunodeficiency virus RNA in plasma and cellular viral DNA genotypic zidovudine resistance and viral load during zidovudine-didanosine combination therapy. J. Virol. 69:3510-3516.
29. Huang, H., R. Chopra, G. L. Verdine, and S. C. Harrison. 1998. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282:1669-1675.
30. Ikuta, K., M. Kameoka, and R. B. Luftig. 1997. AIDS pathogenesis: the role of accessory gene mutations, leading to formation of long-lived persistently infected cells and/or apoptosis-inducing HIV-1 particles. Virus Res. 52: 145-156.
31. Japour, A. J., D. L. Mayers, V. A. Johnson, D. R. Kuritzkes, L. A. Beckett, J. M. Arduino, J. Lane, R. J. Black, P. S. Reichelderfer, R. T. D'Aquila, C. S. Crumpacker, and The AIDS Clinical Trials Group Virology Committee Resistance Working Group. 1993. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 37:1095-1101.
32. Kuritzkes, D. R., I. Marschner, V. A. Johnson, R. Bassett, J. J. Eron, M. A. Fischl, R. L. Murphy, K. Fife, J. Maenza, M. E. Rosandich, D. Bell, K. Wood, J.-P. Sommadossi, C. Pettinelli, and the National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators. 1999. Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators. AIDS 13:685-694.
33. Mammano, F., C. Petit, and F. Clavel. 1998. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J. Virol. 72:7632-7637.
34. Melegari, M., P. P. Scaglioni, and J. R. Wands. 1998. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 27:628-633.
35. Nagylaki, T. 1992. Introduction to theoretical population genetics, p. 25-27. Springer-Verlag KG, Berlin, Germany.
36. Pantaleo, G., A. De Maria, S. Koenig, L. Butini, B. Moss, M. Baseler, H. C. Lane, and A. S. Faucl. 1990. CD8+ T lymphocytes of patients with AIDS maintain normal broad cytolytic function despite the loss of human immunodeficiency virus-specific cytotoxicity. Proc. Natl. Acad. Sci. USA 87:4818-4822.
37. Perelson, A. S., A. U. Neumann, M. Markowitz, J. M. Leonard, and D. D. Ho. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582-1586.
38. Quan, Y., Z. Gu, X. Li, Z. Li, C. D. Morrow, and M. A. Wainberg. 1996. Endogenous reverse transcription assays reveal high-level resistance to the triphosphate of (-)2′-dideoxy-3′-thiacytidine by mutated M184V human immunodeficiency virus type 1. J. Virol. 70:5642-5645.
39. Schooley, R. T., C. Ramirez-Ronda, J. M. A. Lange, D. A. Cooper, J. Lavelle, L. Lefkowitz, M. Moore, B. A. Larder, M. St. Clair, J. W. Mulder, R. McKinnan, K. Pennington, P. R. Harrigan, I. Kinghorn, M. Skol, J. F. Rooney, and Wellcome Resistance Study Collaborative Group. 1996. Virologic and immunologic benefits of initial combination therapy with zidovudine and zalactabine or didanosine compared to zidovudine monotherapy. J. Infect. Dis. 173:1354-1366.
40. Shafer, R. W., A. K. N. Iversen, M. A. Winters, E. Aguiniga, D. A. Katzenstein, T. C. Merigan, and the AIDS Clinical Trials Group 143 Virology Team. 1995. Drug resistance and heterogenous long-term virologic response of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. J. Infect. Dis. 172:70-78.
41. Sharma, P. L., and C. S. Crumpacker. 1997. Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation. J. Virol. 71:8846-8851.
42. Sharma, P. L., P. A. Chatis, A. L. Dogon, D. L. Mayers, F. E. McCutchan, C. Page, and C. S. Crumpacker. 1996. AZT related mutation Lys70Arg in reverse transcriptase of human immunodeficiency virus confers decrease in susceptibility to ddATP in in vitro RT assay. Virology 223:365-369.
43. St. Clair, M., J. Martin, G. Tudor-Williams, M. Bach, C. Vavro, D. King, P. Kellam, S. Kemp, and B. Larder. 1991. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253: 1557-1559.
44. Wei, X., S. K. Ghosh, M. E. Taylor, V. A. Johnson, E. A. Emini, P. Deutsch, J. D. Lifson, S. Bonhoeffer, M. A. Nowak, B. S. Han, M. S. Saag, and G. M. Shaw. 1995. Viral dynamics in human immunodeficiency virus type 1. Nature (London) 373:117-122.
45. Wong, J. K., M. Hezareh, H. F. Gunthard, D. V. Havlir, C. C. Ignacio, C. A. Spina, and D. D. Richman. 1997. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278:1291-1295.
46. Zennou, V., F. Mammano, S. Paulous, D. Mathez, and F. Clavel. 1998. Loss of viral fitness associated with multiple gag and gag-pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J. Virol. 72:3300-3306.